Skip to main content
SpringerLink
Log in

Der medikamentöse Schwangerschaftsabbruch bis 9 + 0 SSW

  • Chapter
  • First Online:
Schwangerschaftsabbruch und gestörte Frühschwangerschaft

  • 2074 Accesses

Zusammenfassung

Der medikamentöse Schwangerschaftsabbruch (mSAB) ist in Deutschland bis 9 + 0 SSW p. m. zugelassen. Zur Dosierung und Applikation von Mifepriston und Misoprostol gibt es unterschiedliche Empfehlungen. In internationalen Leitlinien hat sich die Therapie mit 200 mg Mifepriston oral und nach 36–48 h 400–800 µg Misoprostol vaginal, bukkal oder sublingual durchgesetzt. Im Folgenden wird der genaue Ablauf und eine mögliche Begleitmedikation beschrieben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 34.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 44.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Abubeker FA, Lavelanet A, Rodriguez MI, Kim C (2020) Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review. BMC Women's Health volume 20, Article number: 142

    Google Scholar 

  2. Guest J, Chien PFW, Thomson MAR, Kosseim ML (2007 Feb) Randomized controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol. BJOG 114(2):207–215. https://doi.org/10.1111/j.1471-0528.2006.01179.x

    Article  CAS  PubMed  Google Scholar 

  3. https://www.fpz-berlin.de/Schwangerschaftsabbruch-884834.html. Zugegriffen 23. Mai 21

  4. WHO Medical management of abortion (2018). https://www.who.int/reproductivehealth/publications/medical-management-abortion/en/

  5. Abortion care NICE guideline [NG140] (2019). https://www.nice.org.uk/guidance/ng140. Zugegriffen: 11. März 2021

  6. ACOG Clinical guidance: Medication Abortion Up to 70 Days of Gestation. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2020/10/medication-abortion-up-to-70-days-of-gestation. Zugegriffen: 11. März 2021

  7. AWMF Geburtseinleitung. (2020). https://www.awmf.org/leitlinien/detail/ll/015-088.html. Zugegriffen: 2. April 2021

  8. Kopp Kallner H, Fiala C, Stephansson O, Gemzell-Danielsson K (2010 Feb 19) Home self-administration of vaginal misoprostol for medical abortion at 50–63 days compared with gestation of below 50 days, Hum Reprod. 2010 May 25(5):1153–7. doi: https://doi.org/10.1093/humrep/deq037.Epub

  9. 218. Stellungnahme der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe zum Vorgehen beim medikamentösen Schwangerschaftsabbruch (2015) https://www.dggg.de/fileadmin/documents/stellungnahmen/aktuell/2015/218_Stellungnahme_zum_Vorgehen_beim_medikatmentoesen_Schwangerschaftsabbruch.pdf. Zugegriffen: 11. März 2021

  10. Aiken ARA, Lohr PA, Lord J, Ghosh N, Starling J (2021) Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study. BJOG. https://doi.org/10.1111/1471-0528.16668.00:1-11

    Article  PubMed  PubMed Central  Google Scholar 

  11. https://www.figo.org/abortion-access-and-safety-covid-19-march-2020-guidance. Zugegriffen 23. Mai 21

  12. Kapp N (2014) Pain management in abortion care https://fiapac.org/media/docs/40_Kapp.pdf, Zugegriffen: 21. Dez. 2020

  13. Dragoman MV, Grossman D, Nguyen MH, Habib N, Kapp N, Tamang A, Bessenaar T, Duong LD, Gautam J, Yoko JL, Hong M, Gulmezoglu M (2021 Mar) Two prophylactic pain management regimens for medical abortion ≤63 days’ gestation with mifepristone and misoprostol: A multicenter, randomized, placebo-controlled trial. Contraception 103(3):163–170. https://doi.org/10.1016/j.contraception.2020.12.004 Epub 2021 Jan 13 PMID: 33451721

    Article  CAS  PubMed  Google Scholar 

  14. American Psychological Association (APA), Report of the task force on mental health and abortion. Washington (2008). https://www.apa.org/pi/women/programs/abortion/mental-health.pdf. Zugegriffen 11. März 2021

  15. Cleland K, Creinin MD, Nocatola D, Nshom M, Trussell J (2013 Jan) Significant adverse events and outcomes after medical abortion. Obstet Gynecol 121(1):166–171. https://doi.org/10.1097/aog.0b013e3182755763

    Article  PubMed  PubMed Central  Google Scholar 

  16. Chen MJ, Creinin MD (2015 Jul) Mifepristone With Buccal Misoprostol for Medical Abortion: A Systematic Review. Obstet Gynecol 126(1):12–21. https://doi.org/10.1097/AOG.0000000000000897

    Article  CAS  PubMed  Google Scholar 

  17. Iyengar K, Paul M, Iyengar SD, Klingberg-Allvin M, Essèn B, Bring J (2015) Self-assessment of the outcome of early medical abortion versus clinic follow-up in India: A randomized, controlled, non-inferiority trial. The Lancet Global Health 3, ISSUE 9, E537-E545

    Google Scholar 

  18. Moseson H, Herold S, Filippa S, Barr-Walker J, Baum SE, Gerdts C (2020 Feb) Self-managed abortion: A systematic scoping review. Best Pract Res Clin Obstet Gynaecol 63:87–110. doi: https://doi.org/10.1016/j.bpobgyn.2019.08.002. Epub 2019 Aug 22. PMID: 31859163

  19. Srivastava A, Saxena M, Percher J, Diamond-Smith N (2019 May) Pathways to seeking medication abortion care: A qualitative research in Uttar Pradesh, India. PLoS One 14(5):e0216738. doi: https://doi.org/10.1371/journal.pone.0216738. PMID: 31083665; PMCID: PMC6513085.

  20. Huda FA, Afrin S, Sarker BK, Mahmood HR, Alam A (2017). „Introduction and Approval of Menstrual Regulation with Medication in Bangladesh: A Stakeholder Analysis“ STEP UP Research Report. Dhaka: icddr,b.

    Google Scholar 

  21. www.rcog.org.uk/globalassets/documents/guidelines/early-medical-abortion-at-home-guideline-england.pdf. Zugegriffen 23. Mai 21

  22. Porter Erlank C, Lord J, Church K (2020) Early medical abortion using telemedicine – acceptability to patients. medRxiv 2020.11.11.20229377. doi:https://doi.org/10.1101/2020.11.11.20229377

  23. Aiken ARA, Digol I, Trussell J, Gomperts R (2017) Self reported outcomes and adverse events after medical abortion through online telemedicine: Population based study in the Republic of Ireland and Northern Ireland; BMJ 2017;357:j2011

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Berlin, Deutschland

    Jana Maeffert & Christiane Tennhardt

Authors
  1. Jana Maeffert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christiane Tennhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jana Maeffert .

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Der/die Autor(en), exklusiv lizenziert durch Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Maeffert, J., Tennhardt, C. (2021). Der medikamentöse Schwangerschaftsabbruch bis 9 + 0 SSW. In: Schwangerschaftsabbruch und gestörte Frühschwangerschaft. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-63517-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-63517-9_3

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-63516-2

  • Online ISBN: 978-3-662-63517-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation